SCHEMBL16167

SCHEMBL16167

O=C(c1ccc(N2CCN(S(=O)(=O)c3ccccc3)CC2)cc1)C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.65
ALDH1A1 P00352 7/20 0.57
HPGD P15428 1/20 0.57
HTT P42858 1/20 0.56
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
USP2 O75604 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
TP53 P04637 1/20 0.53
NAMPT P43490 1/20 0.53
TSHR P16473 2/20 0.52
HSD17B10 Q99714 1/20 0.52
MAPT P10636 2/20 0.52
CASP6 P55212 1/20 0.52
LMNA P02545 1/20 0.51
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10901539 0.85 GCK (0.61) GCKALDH1A1HPGDMEN1KMT2A
SCHEMBL12088964 0.82 ALDH1A1 (0.73) GCKALDH1A1HPGDMEN1KMT2A
SCHEMBL18448 0.80 GCK (0.68) GCKHTTMEN1KMT2AUSP2
SCHEMBL616835 0.80 ALDH1A1 (0.78) GCKALDH1A1HPGDHTTMEN1
SCHEMBL16882 0.79 GCK (1.00) GCKALDH1A1HPGDHTT
SCHEMBL17403 0.79 GCK (0.64) GCKALDH1A1HPGDHTTMEN1
SCHEMBL18023 0.77 GCK (0.77) GCKALDH1A1HPGDHTTMEN1
SCHEMBL15754 0.77 GCK (0.77) GCKALDH1A1HPGDHTTMEN1
SCHEMBL12079031 0.77 GCK (0.77) GCKALDH1A1HPGDHTTMEN1
SCHEMBL10902432 0.76 CYP2C9 (0.67) ALDH1A1HTTMEN1KMT2ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 GCK 2/4885ALDH1A1 3293/4885HPGD 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.